Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1B3O

TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE

Summary for 1B3O
Entry DOI10.2210/pdb1b3o/pdb
DescriptorPROTEIN (INOSINE MONOPHOSPHATE DEHYDROGENASE 2), 6-CHLOROPURINE RIBOSIDE, 5'-MONOPHOSPHATE, SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE, ... (5 entities in total)
Functional Keywordsdehydrogenase, impd, impdh, guanine nucleotide synthesis
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight113917.74
Authors
Colby, T.D.,Vanderveen, K.,Strickler, M.D.,Goldstein, B.M. (deposition date: 1998-12-14, release date: 1999-04-12, Last modification date: 2024-12-25)
Primary citationColby, T.D.,Vanderveen, K.,Strickler, M.D.,Markham, G.D.,Goldstein, B.M.
Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.
Proc.Natl.Acad.Sci.USA, 96:3531-3536, 1999
Cited by
PubMed Abstract: Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of cell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides. Two isoforms of IMPDH have been identified, one of which (type II) is significantly up- regulated in neoplastic and differentiating cells. As such, it has been identified as a major target in antitumor and immunosuppressive drug design. We present here the 2.9-A structure of a ternary complex of the human type II isoform of IMPDH. The complex contains the substrate analogue 6-chloropurine riboside 5'-monophosphate (6-Cl-IMP) and the NAD analogue selenazole-4-carboxamide adenine dinucleotide, the selenium derivative of the active metabolite of the antitumor drug tiazofurin. The enzyme forms a homotetramer, with the dinucleotide binding at the monomer-monomer interface. The 6 chloro-substituted purine base is dehalogenated, forming a covalent adduct at C6 with Cys-331. The dinucleotide selenazole base is stacked against the 6-Cl-IMP purine ring in an orientation consistent with the B-side stereochemistry of hydride transfer seen with NAD. The adenosine end of the ligand interacts with residues not conserved between the type I and type II isoforms, suggesting strategies for the design of isoform-specific agents.
PubMed: 10097070
DOI: 10.1073/pnas.96.7.3531
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.9 Å)
Structure validation

237423

數據於2025-06-11公開中

PDB statisticsPDBj update infoContact PDBjnumon